# Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

> **NCT00066677** · PHASE2 · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** rhuMAB-VEGF
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00066677
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-10
- **Primary completion:** 2008-11
- **Final completion:** 2009-04
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Stopped accordining to early stopping rule for futility
- **Last updated:** 2021-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00066677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00066677, "Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00066677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*